vorinostat has been researched along with Blast Phase in 4 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Etoposide combined with vorinostat was additive to synergistic, and the synergism became more pronounced when etoposide was given after vorinostat." | 1.35 | Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. ( Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiozawa, K | 1 |
| Nakanishi, T | 1 |
| Tan, M | 1 |
| Fang, HB | 1 |
| Wang, WC | 1 |
| Edelman, MJ | 1 |
| Carlton, D | 1 |
| Gojo, I | 1 |
| Sausville, EA | 1 |
| Ross, DD | 1 |
| Bhatla, T | 1 |
| Wang, J | 1 |
| Morrison, DJ | 1 |
| Raetz, EA | 1 |
| Burke, MJ | 1 |
| Brown, P | 1 |
| Carroll, WL | 1 |
| Nimmanapalli, R | 1 |
| Fuino, L | 1 |
| Stobaugh, C | 1 |
| Richon, V | 1 |
| Bhalla, K | 1 |
| Rosato, RR | 1 |
| Almenara, JA | 1 |
| Kolla, SS | 1 |
| Maggio, SC | 1 |
| Coe, S | 1 |
| Giménez, MS | 1 |
| Dent, P | 1 |
| Grant, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older[NCT01039363] | Phase 2 | 27 participants (Anticipated) | Interventional | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for vorinostat and Blast Phase
| Article | Year |
|---|---|
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cell Line, Tumor; Child; | 2012 |
3 other studies available for vorinostat and Blast Phase
| Article | Year |
|---|---|
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabi | 2009 |
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle Proteins; Computer Systems; C | 2003 |
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Blast Crisis; Blotting, Western; Butyra | 2007 |